Seattle-based Biotech Startup Talus Bioscience Secures $11.2M in Seed Funding for Cutting-Edge Drug Development Platform

Talus Bioscience, a pioneering early-stage biotechnology startup based in Seattle, WA, is excited to announce that it has successfully raised $11.2 million in its latest funding round. Spun out from the renowned University of Washington and the Altius Institute for Biomedical Sciences in September 2020, Talus Bioscience is at the forefront of drug development, focusing on innovative gene regulators in oncology. This significant investment will bolster Talus Bio’s cutting-edge data-enabled platform, which leverages high-sensitivity quantitative proteomics and advanced analytics to assess a drug’s capability to disrupt gene regulators within their natural cellular environments. The company aims to revolutionize small-molecule drug development, where a single experiment can evaluate the activity of around 1,000 gene regulators simultaneously, thus streamlining the discovery process and enhancing specificity. With this funding, Talus Bio plans to accelerate its internal programs targeting previously undruggable gene regulators associated with cancers that have inadequate standard care options. Additionally, the firm is looking to strengthen collaborations with pharmaceutical, biotech, and academic partners to advance their pipelines of gene regulator therapeutics. The support from our investors enables us not only to expand our research capabilities but also to further validate our unique technological approach within the rapidly evolving biotech landscape. As we continue to explore and unlock the potential of gene regulation for drug discovery, Talus Bioscience is poised to make significant contributions toward transforming cancer treatment outcomes.